Please assess the completion status of the following clinical trial:

Trial Title: The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 20 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960).~* Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study.~Exclusion Criteria:~* Patients with bipolar I or bipolar II disorder~* Patients with personality disorders~* Patients with eating disorders~* Patients with substance dependence or abuse~* Patients with concurrent active medical condition~* Patients with history of seizures~* Patients with history of receiving Electroconvulsive therapy (ECT)~* Patients with inflammatory disorders~* Patients with allergy or contraindications to the used medications~* Patients with finally pregnant or lactating females~* Cardiovascular disorders~* Severe renal impairment: creatinine clearance of ≤ 25 ml/min~* Moderate or severe hepatic impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Escitalopram 20 mg tablet once daily for 6 week plus placebo tablet twice daily for 6 weeks
- Cilostazol group (Type: EXPERIMENTAL): Escitalopram 20 mg tablet once daily for 6 week plus Cilostazol 50mg tablet twice daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).